Publication:
Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat

dc.contributor.authorsLazartigues, E; Freslon, JL; Tellioglu, T; Brefel-Courbon, C; Pelat, M; Tran, MA; Montastruc, JL; Rascol, O
dc.date.accessioned2022-03-12T16:57:22Z
dc.date.accessioned2026-01-11T06:10:22Z
dc.date.available2022-03-12T16:57:22Z
dc.date.issued1998
dc.description.abstractThe cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats. The three drugs significantly increased both systolic and diastolic blood pressure and decreased heart rate. Compared to physostigmine, a 20-fold higher dose of tacrine and a 40-fold higher dose of rivastigmine was necessary to induce a comparable presser effect. Tacrine was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. cholinesterase inhibitors. Atropine totally abolished while methylatropine did not affect tacrine presser effects. Conversely, both drugs abolished tacrine-induced bradycardia. The alpha(1)-adrenoceptor antagonist prazosin or the vasopressin V-1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl(1), O-Me-Tyr(2), Arg(8)] vasopressin partially but significantly reduced tacrine presser effect and mostly abolished it when administered concomitantly. The tacrine presser response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 mu g), the muscarinic M-1 receptor antagonist pirenzepine (ID50 = 4.33 mu g), the muscarinic M-2 receptor antagonist methoctramine (ID50 = 1.39 mu g) and the muscarinic M-3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 mu g). Central injection of such muscarinic receptor antagonists did not affect tacrine-induced bradycardia. Our results show that acetylcholinesterase inhibitors induce significant cardiovascular effects with a presser response mediated mainly by the stimulation of central muscarinic M-2 receptors inducing a secondary increase in sympathetic outflow and vasopressin release. Conversely, aretylcholinesterase inhibitor-induced bradycardia appears to be mediated by peripheral muscarinic mechanisms. (C) 1998 Elsevier Science B.V. All rights reserved.
dc.identifier.doi10.1016/S0014-2999(98)00717-1
dc.identifier.issn0014-2999
dc.identifier.pubmed9851542
dc.identifier.urihttps://hdl.handle.net/11424/226929
dc.identifier.wosWOS:000077243300007
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofEUROPEAN JOURNAL OF PHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectacetylcholinesterase inhibitor
dc.subjectblood pressure
dc.subjectvasopressin
dc.subjectM2 MUSCARINIC RECEPTORS
dc.subjectALZHEIMERS-DISEASE
dc.subjectBLOOD-PRESSURE
dc.subjectCHOLINERGIC MECHANISMS
dc.subjectBRAIN ACETYLCHOLINE
dc.subjectSDZ ENA-713
dc.subjectHYPERTENSION
dc.subjectVASOPRESSIN
dc.subjectRELEASE
dc.subjectPHYSOSTIGMINE
dc.titlePressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage71
oaire.citation.issue1
oaire.citation.startPage61
oaire.citation.titleEUROPEAN JOURNAL OF PHARMACOLOGY
oaire.citation.volume361

Files